Primary IgA Nephropathy (IgAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

IgA nephropathy (IgAN), the most prevalent form of primary glomerulonephritis globally, significantly contributes to chronic kidney disease and end-stage renal disease. It presents a diverse clinical and pathological course and is likely a group of diseases within the primary IgAN entity. It can also manifest secondary to various conditions like liver disease, coeliac disease, and several rheumatological disorders. Primary IgAN can present massive proteinuria (24-h urinary protein ≥3.5 g/d), with or without nephrotic syndrome (NS). Patients with ‘typical’ primary IgAN are categorized into three risk groups: low, intermediate, and high. Low-risk patients exhibit minor urinary abnormalities, normal GFR, and normotension. They require regular follow-up visits, which can be challenging to achieve in asymptomatic young individuals who need persuasion about the importance of regular review. Intermediate-risk patients have ‘significant’ proteinuria (mostly defined as >1 g per day but sometimes also as >0.5 g per day), which can be variably associated with hypertension and a slow reduction in GFR. A crucial subgroup of these patients is those with advanced CKD (eGFR <30–50ml/min/1.73m2) at the time of IgAN diagnosis. High-risk patients experience a rapid loss of GFR.

Thelansis’s “Primary IgA Nephropathy (IgAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary IgA Nephropathy (IgAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Primary IgA Nephropathy (IgAN) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Primary IgA Nephropathy (IgAN) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Primary IgA Nephropathy (IgAN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033